Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin epicardial fat pad injections to prevent postoperative atrial fibrillation after cardiac surgery
2018-002541-11Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of botulinum toxin type A in Atrial fibrillation (AFib) and Atrial tachyarrhythmia (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Incidence of new-onset postoperative atrial fibrillation at 3 months. Started Feb 2019; status: active.
02
Drugs
botulinum toxin type A
03
Conditions
Atrial fibrillation (AFib)Atrial tachyarrhythmia
Beyond the preview
Go deeper on 2018-002541-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002541-11.